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The aim of this review is to explore some of the terminology and contentions surrounding 
CKD classification and identification. The rationale for having a sixth CKD stage is 
explored as an alternative to stages 3A and 3B. In addition, some emphasis on the National 
Institute for Health and Care Excellence (NICE) guidelines are highlighted (1,2). 
Chronic kidney disease (CKD) is a long-term condition in which reduced renal 
function is evident and/or damaged kidneys are unable to 
filter blood to achieve normal physiology (3). With a growing ageing population, CKD 
is a major public health concern; it costs the UK £1.02 billion to prevent acute kidney 
injury (AKI), which results in a higher risk of death than myocardial infarction (MI), 
breast cancer, heart failure and diabetes.  
Owing to increasing prevalence of ‘primary diseases’, there is a higher risk of 
developing CKD and there are also other factors that have an impact on disease state, 
including socioeconomic status, age, gender and Ethnicity(4).  
The epidemiology of CKD in the UK has been outlined in various guidelines,3,4 and 
informed by primary data from the Health Survey for England (HSE) in 2009 and 2010 
using eGFR and albuminuria.9 The prevalence of CKD has risen and there are several 
determinants that need to be challenged, particularly risk factors relating to type 2 
diabetes, hypertension and obesity. One study has found that CKD is often 
undetectable and often asymptomatic (10); however, it is recognised with other pre-
existing conditions such as diabetes and cardiovascular disease (CVD). As CKD 
progresses, although symptoms may go unnoticed, it can escalate to advanced CKD 
(established renal failure [ERF], CKD stage 4). 
Some investigators describe acute renal failure (ARF) as acute kidney injury (AKI) 
and acute and/or chronic renal failure (CRF). These terms have been used 
interchangeably in studies that focused purely on ARF patients with an abnormal 
eGFR (5–7). Studies have recalled patients with a reduced baseline kidney function 
(normally eGFR <45 mL/min per 1.73 m2). Some of the many cases that required 
haemodialysis (HD) were called ‘acute’ (i.e. potentially CKD stages 3–5) and were 
associated with higher rates of morbidity and mortality. However, ESRD; (CKD 
stage 5) is at the severe end of the disease spectrum where patients require a form 
of renal replacement therapy (RRT; e.g. HD) until a kidney for transplantation 
becomes available.  
The issue here is that terminology becomes confusing and there is too much 
‘overlap’ for each CKD stage. This issue is not new and there needs to be more 
systematic review addressing this issue to provide transparency and justification 
between CKD stages. 
It is important to appreciate that there are different definitions in the literature for 
what separates acute from chronic disease in addition to what separates chronic 
disease and chronic illnesses (8). In relation to CKD terminology, this can cause 
confusion in classification and also identification. Chronic kidney disease is often 
‘silent’, and an increasing issue in different populations, causing immense human 
morbidity and mortality (9).  
An online calculator is available to check creatinine level (10), and eGFR can assess 
renal function to confirm an initial diagnosis. Despite variations in terminology, 
guidelines and frameworks (11) divide and endorse classification with a fixed renal 
impairment grading (mild, moderate and severe) (12). Other workers (13) 
recognise CKD by the prevalence of CKD stages 1–5 (including stage 3 separated 
into 3A and 3B, where stage 3A is categorised as an eGFR 54–59 mL/min/1.73 m2 
and stage 3B as 30–44 mL/min/1.73 m2). 
Modification of diet in renal disease is the most extensively used equation to 
calculate eGFR based on other variables; however, prevalence rises with age and 
is found to be more common in females than in males. The epidemiological 
importance of ethnicity has not been completely articulated, although a review (23) 
has studied a South Asian ethnic minority group and compared it to UK and US 
populations. Table 1 summarizes the traditional 5-stages of CKD by GFR. 
Over the past decade there have been efforts to improve the identification, 
management and monitoring of CKD. While there are five stages of CKD, one review 
(14) suggests that AKI also has four categories; i) vascular, a condition in which blood 
vessels are obstructed; ii) glomerular, a histological type involving an immune 
element normally associated with nephrotic syndrome (NS) and proteinuria >3 g/24 
h, oedema and hypoalbuminaemia; iii) tubular, involving acute tubular nephrosis 
(ATN) with renal impairment; and iv) interstitial, which is not 
associated with the previous three categories. An example could be where there is 
presence of eosinophils, which may be drug-related and cause ARF. Nocturia, 
anaemia, long-standing hypertension and neuropathy are all associated with of CKD. 
Acute kidney injury is divided into four stages which are dependent on creatinine 
results within 48 hours and also urine output. Table 2 summarises the stages of AKI. 
• Stage 5 can also be termed ESRD and sometimes even end-stage renal failure 
(ESRF). While this means that terminology associated with CKD stages can be 
interchangeable, it also causes confusion when providing patients with advice 
and care. 
• What defines advanced CKD (ACKD)? Should this be CKD stage 4? There is a 
need to develop plans to screen patients who are at risk earlier to minimise 
further complications. 
• Stage 3 is subdivided (stages 3A and 3B), but 1) the eGFR ranges are quite 
narrow between the two, so is there a good reason for the division? 2) Both 
subdivisions need to be accompanied by the appropriate terminology if the 
present classification and identification system continues, even if revised. 
• There is not always a consensus among health professionals and in the coding 
related terminology (eg AKI, ESRD and ARF). This is where there can be 
misinterpretation and confusion with respect to stage and classification. 
• Clear definitions/terminology that relate to staging has been outlined in detail 
(17), but patients should know exactly what classification of CKD they have, 
and the appropriate terminology or definition, whereby they are empowered 
to gain wider resources and knowledge to support their healthcare 
requirements. 
• Guidelines on the management of CKD indicate that patients should have frequent 
tests to monitor those at risk using eGFR and albumin: creatinine ratio (ACR) <3 
mg/mmol, and look for any other indications of renal Disease (1). Another 
amendment to the guidelines involves not testing people with eGFR creatinine of 45–
59 mL/min/1.73 m2 at stage 3A.  
• However, if patients are not tested during the early stages of CKD then diagnosis will 
be delayed and the opportunity for early intervention to slow progression of the 
disease with be missed. Patients in stages 3A and 3B require six monthly checks of 
eGFR; however, this split classification can result in confusion, and it is suggested 
that a further stage (stage 6) be included and that stages 3A and 3B be replaced by a 
single stage 3 because the eGFR margin is already narrow.  
• There should also be appropriate terms associated with all stages, and there should 
be wider screening opportunities and collaborations.  
• In conclusion, this article aims to put CKD guidelines into context in terms of disease 
onset and progression to ESRD, AKF, ESKD, CRF and RRT, as currently there is no 
consensus on how these terms (with the exception of RRT) are being used.  
• Scientists and renal teams who have knowledge of clinical parameters and specialist 
understanding should also be involved in future discussion, as more health 
promotion is required in this critical area. 
The ‘new’ classification for CKD stages proposed in a review (15) removes the subdivision 
of stage 3 (3A and 3B). Patients with stage 3B would require an earlier referral than those 
with stage 3A for special renal care. Earlier detection will prolong the CKD stage and 
therefore intervention will occur at an earlier stage, slowing down CKD progression. 
Furthermore, the methodological procedures to calculate the risks involved for treatment 
and diagnostic delay in CKD have been examined (16). Analytical data collected recently 
(28) looked at coded or uncoded CKD patients and their relationship to stages 3–5. The 
results broke down into ‘confirmed CKD’, ‘labelled CKD’, ‘appropriately coded’, ‘uncoded 
CKD’ and ‘miscoded CKD’. Patients labelled ‘miscoded CKD’ received treatment at a much 
later stage, with a higher risk of co-morbidities. Table 3 summarizes a definition and 
terminology  proposal. 
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